Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
Hng dn s dng Ung 1 vin/ngy trong ba n c hiu qu cao nht
At Lone Star Center for Health and Wellness, we understand that each individual has unique health needs
Pharmacological activity and clinical use of PDRN
it has key roles in appetite regulation, insulin secretion to lower blood sugar, and slowing the digestive system
